Arbutus approved one-time litigation-related cash bonuses: CEO Lindsay Androski to receive 1.5% of the company's noncontingent settlement payment (with additional contingent awards possible) and CFO Tuan Nguyen to receive a 0.25% discretionary bonus tied to the noncontingent payment.
| IndividualLindsay AndroskiTuan Nguyen | RolePresident and Chief Executive OfficerChief Financial Officer | Type of ChangeAppointed to receive litigation-related bonusesAppointed to receive litigation-related bonus | Effective DateFirst bonus payable by end of July 2026; additional bonuses conditional upon receipt of related proceedsInitial payment by end of July 2026; remaining payment upon related Genevant Parent dividend (if any) | ReasonIn connection with receipt of the company's share of the Moderna noncontingent settlement payment and related litigation outcomesIn consideration of efforts and accomplishments associated with the Moderna settlement | Replacement InfoNot disclosedNot disclosed | Background DetailsBonus Agreement provides: 1.5% of noncontingent settlement payment; 2.0% of contingent Moderna-related proceeds; 2.5% of proceeds from Pfizer/BioNTech litigation; excludes amounts received as dividend from Genevant Parent.First Nguyen Litigation Bonus: 0.25% of proceeds from noncontingent settlement (including any Genevant Parent dividend). Future bonus: discretionary 0.25% of remaining Moderna-related proceeds; board may alter or terminate. | Board/Committee Role ChangesNot disclosedNot disclosed |
Original SEC Filing:
This is an AI-powered summary. It may contain inaccuracies. Consider verifying important information with the source. Please note this summary is solely based on documents filed with the SEC.